A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 5, 2014

Early Trial Raises Hopes of Quarterly PrEP Injections

CROI 2014An injectable long-acting antiretroviral succeeded in preventing rectal acquisition of SIV, the simian cousin of HIV, among monkeys, opening the door for a possible form of pre-exposure prophylaxis (PrEP) that requires only quarterly injections, The New York Times reports. Researchers published their findings in Science and also presented them at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The scientists injected eight rhesus macaque monkeys with the long-acting integrase inhibitor GSK1265744 (GSK744 LA) at two points separated by four weeks. A week after the first injection, these monkeys, as well as eight untreated others who served as a control, received eight weekly rectal exposures to SIV. The control animals acquired SIV after an average of two exposures, while none of the treated monkeys were infected.

The results offer promising news for the future of PrEP, considering that trials of Truvada (tenofovir/emtricitabine) have shown that most people taking the daily pill to prevent HIV acquisition adhere poorly to the drug regimen and as a consequence the drug is less effective. A periodic injection could help to solve the adherence problem.

“We are encouraged by the results of these animal studies,” Martin Markowitz, a co-investigator on this study and the clinical director at the Aaron Diamond AIDS Research Center and Aaron Diamond Professor at the Rockefeller University, said in a release. “Perhaps most exciting is that the levels of drug that were fully protective in this animal model are readily achievable in man with quarterly injections of GSK744 LA and these data form the rationale for taking the agent into initial clinical studies.”

A Phase II trial of GSK744 LA, in which the drug will be given to men at low risk for HIV, will begin in the next few months. This will lay the groundwork for a Phase III study of high-risk individuals that will ultimately determine the drug’s efficacy as a means of HIV prevention.

To read the New York Times story, click here.

[Note, the Times erroneously states that in previous studies of daily oral PrEP “the only participants protected were those who took their pills every day without fail.” In fact, those who adhered perfectly to the medication regimen were the only ones who were totally protected. Those who did not adhere perfectly to the PrEP regimen in these trials were still less likely to acquire HIV than those who did not take PrEP at all, but the regimen did not eliminate their risk entirely. The Times also incorrectly states that the injections prevented AIDS in monkeys, rather than SIV. In order for an HIV therapy to prevent AIDS, the monkeys would have to be infected with the virus that causes AIDS.  On the contrary, this study concerned preventing transmission in the first place.]

Search: PrEP, pre-exposure prophylaxis, SIV, HIV, simian, The New York Times, quarterly injections, long-acting, GSK1265744, GSK744 LA, Conference on Retroviruses and Opportunistic Infections, CROI, Truvada, tenofovir, emtricitabine, Aaron Diamond, Martin Markowitz.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.